Abstract| Volume 42, ISSUE 5, SUPPLEMENT , S43-S44, October 2018

The Influence of SGLT-2 Inhibitors and Other Glucose- Lowering Therapies on Mortality Risk in Elderly Patients with Type 2 Diabetes

      Background: SGLT-2 inhibitors (SGLT-2i) have been associated with decreased cardiovascular (CV) morbidity and mortality in patients with type 2 diabetes (T2DM). The objective of this study was to measure the association of SGLT-2i and other oral glucose-lowering drugs (oGLD) on all-cause mortality in elderly patients with newly diagnosed T2DM.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect